Breaking News, Collaborations & Alliances

Ultragenyx and Takeda Collaborate on Rare Genetic Diseases

Ultragenyx to license and develop one or more product candidates from Takeda

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Ultragenyx Pharmaceutical, a biopharmaceutical company focused on the development of novel products for rare and ultra-rare genetic diseases, and Takeda Pharmaceutical, have formed a partnership to develop and commercialize therapies to treat rare genetic diseases. Ultragenyx will initially receive an exclusive license to one preclinical Takeda product candidate in a pre-determined field of use, and will have an exclusive option to co-develop and co-commercialize the product candidate in addi...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters